5 PARK PLAZA, IRVINE, CA
Receives Additional Notice Related to NYSE American Continued Listing Standards
Financial Results, Press Release
Appointment of John Bencich as Chief Financial Officer
Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions
Investor Presentation
Announces Execution of Exchange Agreement with Daewoong
Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth
FY 2025
Q3
Q2
Amended Annual Report
Amended Quarterly Report
Q1
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Schedule 13D - Ownership Report
Definitive Revised Proxy Statement